Live tape
Top 8, mentions 7d30,017NVDA14,564 mentions▲ +0.04ANT4,160 mentions▲ +0.06GOOGL2,936 mentions▲ +0.04SPY2,248 mentions▲ +0.05QQQ1,804 mentions▲ +0.04SPCX1,748 mentions▲ +0.08AMD1,367 mentions▲ +0.06AAPL1,190 mentions▲ +0.04

Equity · Healthcare

COGT

NASDAQ

Cogent Biosciences (COGT)

26.71 USD −3.75% vs prior close Nov 20, 2026
Cogent Biosciences, Inc. price graph
50 sessions
34 26 14 Sep 20 Nov

The line runs 33 USD on 14 September through 26.71 USD on 20 November, on a scale from 26 to 34. Days the market did not trade hold the previous close, flat.

Market cap
4.6B USD
EPS, diluted, year to Dec 2025
−2.16 USD
52-week range
26.71 USD – 43 USD
Avg volume
131.6K

as of Nov 20, 2026

Have Cogent Biosciences (COGT) insiders bought or sold shares recently?

In the 90 days to 22 Nov 2026, Cogent Biosciences insiders reported 1 open-market sale and no purchases (SEC Form 4); the filings we hold, back to 17 Dec 2025, show no open-market purchase.

Form 4, 90 days to 22 Nov 2026, newest reported trade 27 Aug 2026

0buys
1sells
$1.69Mnet sold
1other filings
Have Cogent Biosciences (COGT) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
27 Aug 2026Morris ArleneDirectorSell45,5101.7M USD
1 other filing in the window: a grant, exercise, tax withholding or transfer, not a trade
Have Cogent Biosciences (COGT) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
27 Aug 2026Morris ArleneDirectorOption exercise45,510245K USD

Which funds hold Cogent Biosciences (COGT)?

11 of the 45 institutional funds we track reported a Cogent Biosciences position for the quarter ended 30 Sep 2026 — a combined 156.3M USD; the latest of those filings landed 16 Nov 2026.

Form 13F

Which funds hold Cogent Biosciences (COGT)?
FundPositionSharesValueShares q/q
Citadel AdvisorsHeld (±25%)990,01031.7M USD+16.5%
Balyasny Asset ManagementHeld (±25%)813,28126.0M USD−14.8%
Point72 Asset ManagementHeld (±25%)790,49425.3M USD+6.2%
Renaissance TechnologiesTrimmed708,66822.7M USD−28.9%
D. E. Shaw & Co.Trimmed406,10213.0M USD−56.0%
Millennium ManagementTrimmed324,67210.4M USD−64.2%
Marshall WaceTrimmed270,6108.7M USD−61.7%
Duquesne Family OfficeNew position221,1127.1M USD
AQR Capital ManagementTrimmed162,1125.2M USD−45.0%
Fisher Asset ManagementHeld (±25%)152,4984.9M USD−17.5%

Showing the 10 largest of 11 reported positions. The figures above count all of them.

Have members of Congress traded Cogent Biosciences (COGT)?

The most recent congressional trade disclosed in Cogent Biosciences is a purchase by Sara Jacobs (house, CA), dated 12 Dec 2022.

STOCK Act disclosures

Have members of Congress traded Cogent Biosciences (COGT)?
TradedMemberTypeAmountFiled after
12 Dec 2022Sara Jacobshouse · Democrat–CAPurchase1K USD–15K USD39 days

What has been filed or recorded for Cogent Biosciences (COGT)?

The filings we hold for Cogent Biosciences, newest first: 2 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 4 reported financial figures, the latest dated 22 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Cogent Biosciences (COGT)?
And
22 Oct 2026Fails to deliverShares failed to deliver100 shares3K USD notional · <0.001% of shares out
09 Oct 2026Fails to deliverShares failed to deliver8 shares241 USD notional · <0.001% of shares out
30 Sep 2026Quarterly earningsQ3 2026 reportedEPS −0.59 USD
30 Sep 2026FinancialsTotal assets832.1M USDat period end
30 Sep 2026FinancialsTotal equity516.3M USDat period end
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS −0.52 USD
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −0.53 USD
31 Dec 2025Annual reportFY 2025 reportedEPS −2.16 USD
31 Dec 2025FinancialsNet income−328.9M USDfiscal year
31 Dec 2025FinancialsDiluted EPS−2.16 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −0.50 USD
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −0.53 USD
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −0.52 USD
31 Dec 2024Annual reportFY 2024 reportedEPS −1.94 USD

What do people ask about Cogent Biosciences (COGT)?

From live data
What did Cogent Biosciences shares close at?26.71

Cogent Biosciences closed at 26.71 USD on 20 Nov 2026, down 3.75% on the close before. That is the end-of-day price from Finazon, not a live quote.

What is Cogent Biosciences’ market cap?4.6B

Cogent Biosciences is worth 4.6B USD by market value as of 20 Nov 2026, which is the share price times the shares on issue from its SEC filings.

Have Cogent Biosciences insiders bought or sold shares recently?1 sale

In the 90 days to 22 Nov 2026, Cogent Biosciences insiders reported 1 open-market sale and no purchases (SEC Form 4); the filings we hold, back to 17 Dec 2025, show no open-market purchase. A further 1 filing was a grant, award, gift or exercise rather than an open-market trade. See Insiders

Which funds own Cogent Biosciences?11 of 45

11 of the 45 funds we track reported a Cogent Biosciences position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Citadel Advisors, Balyasny Asset Management and Point72 Asset Management. See Funds

Have members of Congress traded Cogent Biosciences?1 trade

Yes. 1 trade in Cogent Biosciences appears in the congressional disclosures we hold: a purchase by Sara Jacobs (House, CA) dated 12 Dec 2022, filed 20 Jan 2023. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress

When did Cogent Biosciences last report earnings?−0.59

Cogent Biosciences last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.59 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. Wikimedia CommonsPortraits via Wikimedia Commons. Sara Jacobs: Kristie Baxter, Public domain.
  6. House disclosuresU.S. House of Representatives financial disclosures
  7. SECSEC fails-to-deliver (CNS) data
  8. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  9. SEC EDGARreported earnings figures and scheduled report dates
  10. SEC EDGARValuation computed from SEC EDGAR filings
  11. SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words